MA35361B1 - Inhibiteurs selectifs et reversibles de la protease 7 specifiques a l'ubiquitine - Google Patents
Inhibiteurs selectifs et reversibles de la protease 7 specifiques a l'ubiquitineInfo
- Publication number
- MA35361B1 MA35361B1 MA36781A MA36781A MA35361B1 MA 35361 B1 MA35361 B1 MA 35361B1 MA 36781 A MA36781 A MA 36781A MA 36781 A MA36781 A MA 36781A MA 35361 B1 MA35361 B1 MA 35361B1
- Authority
- MA
- Morocco
- Prior art keywords
- ubiquitin
- selective
- specific
- protease
- reversible inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000002441 reversible effect Effects 0.000 title abstract 2
- 101710180012 Protease 7 Proteins 0.000 title 1
- 102000044159 Ubiquitin Human genes 0.000 title 1
- 108090000848 Ubiquitin Proteins 0.000 title 1
- QMNUDYFKZYBWQX-UHFFFAOYSA-N 1H-quinazolin-4-one Chemical class C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 abstract 1
- 101100208731 Caenorhabditis elegans math-33 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000018390 Ubiquitin-Specific Proteases Human genes 0.000 abstract 1
- 108010066496 Ubiquitin-Specific Proteases Proteins 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne des composés de quinazolin-4-one de formule (i'), leur procédé de préparation et leurs utilisations. Ces composés sont utiles comme inhibiteurs sélectifs et réversibles des protéases spécifiques à l'ubiquitine, en particulier l'usp7, pour le traitement par exemple du cancer, de maladies neurodégénératives, de troubles inflammatoires et d'infections virales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11306096A EP2565186A1 (fr) | 2011-09-02 | 2011-09-02 | Inhibiteurs sélectifs et réversibles de la protéase 7 spécifique de l'ubiquitine |
| PCT/EP2012/066741 WO2013030218A1 (fr) | 2011-09-02 | 2012-08-29 | Inhibiteurs sélectifs et réversibles de la protéase 7 spécifique à l'ubiquitine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35361B1 true MA35361B1 (fr) | 2014-08-01 |
Family
ID=46750347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36781A MA35361B1 (fr) | 2011-09-02 | 2014-02-25 | Inhibiteurs selectifs et reversibles de la protease 7 specifiques a l'ubiquitine |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9546150B2 (fr) |
| EP (2) | EP2565186A1 (fr) |
| JP (1) | JP6059228B2 (fr) |
| KR (1) | KR20140085430A (fr) |
| CN (1) | CN103930415B (fr) |
| AR (1) | AR087757A1 (fr) |
| AU (1) | AU2012300944B2 (fr) |
| BR (1) | BR112014004649A2 (fr) |
| CA (1) | CA2847017A1 (fr) |
| CL (1) | CL2014000511A1 (fr) |
| DK (1) | DK2751092T3 (fr) |
| ES (1) | ES2594603T3 (fr) |
| HU (1) | HUE029418T2 (fr) |
| IL (1) | IL231203A (fr) |
| LT (1) | LT2751092T (fr) |
| MA (1) | MA35361B1 (fr) |
| MX (1) | MX340500B (fr) |
| PL (1) | PL2751092T3 (fr) |
| PT (1) | PT2751092T (fr) |
| RU (1) | RU2622640C2 (fr) |
| SG (1) | SG11201400205QA (fr) |
| SI (1) | SI2751092T1 (fr) |
| TN (1) | TN2014000079A1 (fr) |
| WO (1) | WO2013030218A1 (fr) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2565186A1 (fr) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Inhibiteurs sélectifs et réversibles de la protéase 7 spécifique de l'ubiquitine |
| JP2016504365A (ja) | 2012-12-28 | 2016-02-12 | アメリカ合衆国 | Ｕｓｐ１／ｕａｆ１デユビキチナーゼ複合体阻害剤及びその使用 |
| CN105327350A (zh) * | 2014-07-23 | 2016-02-17 | 中国科学院上海巴斯德研究所 | 泛素化途径相关因子在调控辅助性t细胞功能中的应用 |
| MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
| AR103297A1 (es) * | 2014-12-30 | 2017-05-03 | Forma Therapeutics Inc | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina |
| JP2018504431A (ja) * | 2015-02-05 | 2018-02-15 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的プロテアーゼ７阻害物質としてのチエノピリミジノン |
| WO2016126926A1 (fr) | 2015-02-05 | 2016-08-11 | Forma Therapeutics, Inc. | Quinazolinones et azaquinazolinones comme inhibiteurs de la protéase 7 spécifique de l'ubiquitine |
| HK1248221A1 (zh) | 2015-02-05 | 2018-10-12 | Forma Therapeutics, Inc. | 异噻唑啉酮类，吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂 |
| CN105251020B (zh) * | 2015-09-29 | 2018-10-09 | 武汉大学 | 泛素特异性蛋白酶4（usp4）在治疗心肌肥厚中的功能及应用 |
| GB201522267D0 (en) * | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) * | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| FR3052451B1 (fr) * | 2016-06-10 | 2018-06-22 | Les Laboratoires Servier | Nouveaux derives de piperidinyle hetero(aryl)-substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3061177B1 (fr) * | 2016-12-28 | 2019-09-27 | Les Laboratoires Servier | Nouveaux derives piperidinyles hetero(aryle)-substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
| SG11201810576QA (en) * | 2016-06-10 | 2018-12-28 | Servier Lab | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them |
| FR3052452B1 (fr) * | 2016-06-10 | 2018-06-22 | Les Laboratoires Servier | Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2018009812A1 (fr) | 2016-07-08 | 2018-01-11 | Mayo Foundation For Medical Education And Research | Procédés et matériaux de traitement du cancer |
| GB201612938D0 (en) * | 2016-07-26 | 2016-09-07 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201617758D0 (en) * | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| CA3042581A1 (fr) * | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Amelioration de la therapie de blocage des cd47 par des inhibiteurs du proteasome |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| JP7208931B2 (ja) | 2017-06-20 | 2023-01-19 | ミッション セラピューティクス リミティド | Ｄｕｂ阻害剤としての活性をもつ置換シアノピロリジン類 |
| US11465983B2 (en) | 2017-09-26 | 2022-10-11 | Dana-Farber Cancer Institute, Inc. | USP7 inhibitors for treating multiple myeloma |
| GB201801562D0 (en) * | 2018-01-31 | 2018-03-14 | Almac Diagnostics Ltd | Pharmaceutical compounds |
| US12539292B2 (en) | 2018-04-01 | 2026-02-03 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| JP7508449B2 (ja) * | 2018-10-22 | 2024-07-01 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｕｓｐ７の阻害 |
| CN113365696A (zh) * | 2018-12-06 | 2021-09-07 | 阿尔麦克探索有限公司 | 药物化合物和其作为泛素特异性蛋白酶19(usp19)抑制剂的用途 |
| WO2020165315A1 (fr) | 2019-02-14 | 2020-08-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Utilisation d'inhibiteurs de l'usp7 pour le traitement de la leucémie aiguë myéloïde (lam) |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| CA3146715A1 (fr) * | 2019-07-15 | 2021-01-21 | Oncoarendi Therapeutics S.A. | Aminotriazoles substitues utiles en tant qu'inhibiteurs de chitinase |
| GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
| CN113087718B (zh) * | 2020-01-09 | 2024-02-09 | 四川科伦博泰生物医药股份有限公司 | 噻吩并嘧啶酮类化合物及其医药应用 |
| GB202001980D0 (en) | 2020-02-13 | 2020-04-01 | Almac Discovery Ltd | Therapeutic mentods |
| CA3167473A1 (fr) * | 2020-02-28 | 2021-09-02 | Immunologik Gmbh | Inhibiteurs de desubiquitinases humaines pour le traitement d'infections coronavirales |
| CN115461340A (zh) | 2020-04-08 | 2022-12-09 | 特殊治疗有限公司 | 具有作为usp30抑制剂活性的n-氰基吡咯烷类化合物 |
| EP4157332A4 (fr) * | 2020-05-26 | 2024-06-05 | Lowell Therapeutics, Inc. | Procédés de traitement d'une infection virale à l'aide d'inhibiteurs de protéase |
| AU2021279199A1 (en) | 2020-05-28 | 2023-01-19 | Mission Therapeutics Limited | N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as USP30 inhibitors for the treatment of mitochondrial dysfunction |
| IL298710A (en) | 2020-06-04 | 2023-02-01 | Mission Therapeutics Ltd | N-cyanopyrrolidines with activity as USP30 inhibitors |
| IL298785B1 (en) | 2020-06-08 | 2025-11-01 | Mission Therapeutics Ltd | 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis |
| CN112047933B (zh) * | 2020-10-15 | 2022-06-14 | 郑州大学 | 喹唑啉酮类usp7抑制剂及其制备方法和应用 |
| GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
| US20250034122A1 (en) | 2021-12-01 | 2025-01-30 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
| GB202200753D0 (en) | 2022-01-21 | 2022-03-09 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB202408928D0 (en) | 2024-06-21 | 2024-08-07 | Mission Therapeutics Ltd | Novel compounds |
| WO2026015548A1 (fr) * | 2024-07-08 | 2026-01-15 | Convelo Therapeutics, Inc. | Inhibiteurs de cyp51 et leur procédé d'utilisation |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2796417A (en) * | 1952-04-03 | 1957-06-18 | American Cyanamid Co | Quinazolone compounds and methods of making the same |
| US3073826A (en) * | 1960-10-20 | 1963-01-15 | Mead Johnson & Co | 3-pyrrolidylmethyl-4-quinazolones |
| WO1993012795A1 (fr) * | 1985-08-30 | 1993-07-08 | Glazer Edward A | Derives de quinazolin-4(3h)-one utilises comme agents anticoccidiose |
| FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US7842522B2 (en) | 2001-10-19 | 2010-11-30 | Applied Nanotech Holdings, Inc. | Well formation |
| SE0303280D0 (sv) | 2003-12-05 | 2003-12-05 | Astrazeneca Ab | Novel compounds |
| TW200524601A (en) * | 2003-12-05 | 2005-08-01 | Bristol Myers Squibb Co | Heterocyclic anti-migraine agents |
| WO2005095360A1 (fr) * | 2004-04-02 | 2005-10-13 | Prana Biotechnology Limited | Composes neurologiquement actifs |
| SE0401656D0 (sv) | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | Chemical compounds |
| WO2006012577A2 (fr) * | 2004-07-22 | 2006-02-02 | Bayer Pharmaceuticals Corporation | Derives de la quinazolinone utiles pour la regulation de l'homeostasie du glucose et de prise d'aliments |
| US20090118261A1 (en) | 2004-08-31 | 2009-05-07 | Astrazeneca Ab | Quinazolinone derivatives and their use as b-raf inhibitors |
| WO2006072048A2 (fr) | 2004-12-30 | 2006-07-06 | The Trustees Of Princeton University | Compositions et methodes permettant l'identification de modulateurs de hausp |
| US7709516B2 (en) | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
| DE602005010421D1 (de) | 2005-08-05 | 2008-11-27 | Hybrigenics Sa | Neue Cysteine Protease Hemmers und ihre therapeutische Anwendungen |
| JP2009507022A (ja) | 2005-09-06 | 2009-02-19 | スミスクライン ビーチャム コーポレーション | ベンズイミダゾールチオフェン類の位置選択的調製方法 |
| WO2007147217A1 (fr) * | 2006-06-22 | 2007-12-27 | Prana Biotechnology Limited | Procédé de traitement d'une tumeur cérébrale gliome |
| US20080188498A1 (en) * | 2007-02-05 | 2008-08-07 | Radix Pharmaceuticals, Inc. | Pyridopyrimidinone compounds with antimalarial activity |
| JP2011530596A (ja) * | 2008-08-11 | 2011-12-22 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | ｔＲＮＡ合成酵素の阻害のためのハロフジノン類似体およびそれらの使用 |
| US8470819B2 (en) | 2008-11-03 | 2013-06-25 | Merck Sharp & Dohme Corp. | Benzimidazole and aza-benzimidazole carboxamides |
| EP2357176A1 (fr) | 2010-01-15 | 2011-08-17 | Hybrigenics S.A. | Dérivés d'amidoacridine en tant qu'inhibiteurs sélectifs de la protéase 7 spécifique de l'ubiquitine |
| EP2565186A1 (fr) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Inhibiteurs sélectifs et réversibles de la protéase 7 spécifique de l'ubiquitine |
-
2011
- 2011-09-02 EP EP11306096A patent/EP2565186A1/fr not_active Withdrawn
-
2012
- 2012-08-29 DK DK12751080.8T patent/DK2751092T3/en active
- 2012-08-29 PL PL12751080T patent/PL2751092T3/pl unknown
- 2012-08-29 RU RU2014112692A patent/RU2622640C2/ru not_active IP Right Cessation
- 2012-08-29 SI SI201230714A patent/SI2751092T1/sl unknown
- 2012-08-29 MX MX2014002489A patent/MX340500B/es active IP Right Grant
- 2012-08-29 AU AU2012300944A patent/AU2012300944B2/en not_active Ceased
- 2012-08-29 SG SG11201400205QA patent/SG11201400205QA/en unknown
- 2012-08-29 CN CN201280054148.2A patent/CN103930415B/zh not_active Expired - Fee Related
- 2012-08-29 CA CA2847017A patent/CA2847017A1/fr not_active Abandoned
- 2012-08-29 WO PCT/EP2012/066741 patent/WO2013030218A1/fr not_active Ceased
- 2012-08-29 BR BR112014004649A patent/BR112014004649A2/pt not_active Application Discontinuation
- 2012-08-29 ES ES12751080.8T patent/ES2594603T3/es active Active
- 2012-08-29 LT LTEP12751080.8T patent/LT2751092T/lt unknown
- 2012-08-29 HU HUE12751080A patent/HUE029418T2/en unknown
- 2012-08-29 JP JP2014527641A patent/JP6059228B2/ja not_active Expired - Fee Related
- 2012-08-29 US US14/241,923 patent/US9546150B2/en not_active Expired - Fee Related
- 2012-08-29 PT PT127510808T patent/PT2751092T/pt unknown
- 2012-08-29 KR KR1020147007456A patent/KR20140085430A/ko not_active Ceased
- 2012-08-29 EP EP12751080.8A patent/EP2751092B1/fr active Active
- 2012-08-31 AR ARP120103228A patent/AR087757A1/es not_active Application Discontinuation
-
2014
- 2014-02-21 TN TNP2014000079A patent/TN2014000079A1/en unknown
- 2014-02-25 MA MA36781A patent/MA35361B1/fr unknown
- 2014-02-27 IL IL231203A patent/IL231203A/en active IP Right Grant
- 2014-02-28 CL CL2014000511A patent/CL2014000511A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35361B1 (fr) | Inhibiteurs selectifs et reversibles de la protease 7 specifiques a l'ubiquitine | |
| MA35365B1 (fr) | Pyrimidines annelées substituées et leur utilisation | |
| MA49809A1 (fr) | Composés utilisés comme inhibiteurs de kinase | |
| MA42376B1 (fr) | Dérivés d'oxopyridine substitués | |
| MA34248B1 (fr) | 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation | |
| MA33053B1 (fr) | Inhibiteurs de la poly(adp-ribose) polymerase (parp) | |
| MA39170B1 (fr) | Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer | |
| PH12014502183A1 (en) | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof | |
| MX361759B (es) | Compuestos macrocíclicos de dihidropiridona como inhibidores del factor xia y el uso de los mismos en el tratamiento de un trastorno tromboembólico. | |
| MA34909B1 (fr) | Triterpénoïdes modifi2s en c-17 et c-3 presentant une activité inhibitrice de la maturation du vih | |
| MA35193B1 (fr) | Halogeno-alkyl-1,3 oxazines en tant qu'inhibiteurs de bace1 et/ou bace2 | |
| MA35191B1 (fr) | Spiro-[1,3]-oxazines et spiro-[1,4]-oxazepines en tant qu'inhibiteurs de baec1 et/ou bace2 | |
| MX2013007558A (es) | 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2). | |
| MX2009013565A (es) | Derivados de azapeptidos. | |
| EA200802054A1 (ru) | Ингибиторы фермента | |
| MX2013007957A (es) | 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2). | |
| PH12014501967B1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
| EP2563794A4 (fr) | Inhibiteurs de l'activité protéine tyrosine kinase et leurs applications au traitement de troubles ophtalmiques | |
| MA44948A1 (fr) | Inhibiteurs de bace 1 | |
| MX2013014194A (es) | 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2). | |
| MA35444B1 (fr) | Ligands du récepteur ep1 | |
| GEP20125458B (en) | Matrix metalloproteinase inhibitors | |
| MA38296B2 (fr) | Peptides inhibiteurs sélectifs de nox-1 et leurs utilisations | |
| MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
| GEP20094786B (en) | 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases |